The pharmaceutical company said the contract represents 70% of the total tender volume, underscoring its scale, operational readiness and capacity to support nationwide supply requirements.

It said the deal reflects the group’s established manufacturing capabilities, proven execution track record and continued alignment with national healthcare priorities, and strengthens its standing as a key player within the country’s pharmaceutical and healthcare ecosystem.

Pharmaniaga said the contract would also strengthen the group’s recurring revenue base within the public healthcare segment while enhancing earnings visibility over the contract period.

“The award reinforces Pharmaniaga’s growing role in the biopharmaceutical segment, particularly in the production and supply of critical chronic disease treatments such as insulin,” Bernama reported the company as saying.

Pharmaniaga managing director Zulkifli Jafar said the group was honoured to support the health ministry’s healthcare priorities while strengthening its manufacturing and supply chain capabilities.

He said the contract was timely, as ongoing geopolitical developments continue to highlight the importance of building a more resilient and self-reliant domestic pharmaceutical ecosystem.

“Strengthening local manufacturing capabilities, particularly for essential and chronic disease treatments such as insulin, will be critical in safeguarding national medicine security and ensuring sustainable access to treatment for the people in the years ahead,” he said.